[1] SIEGEL R,MA J,ZOU Z,et al.Cancer statistics[J].CA Cancer J Clin,2014,64:9-29.
[2] JIANG X,de GROH M,LIU S,et al.Rising incidence of adenocarcinoma of the lung in Canada[J].Lung Cancer,2012,78:16-22.
[3] 孙燕,马胜林.晚期胃癌药物治疗策略和展望[J].中华肿瘤防治杂志,2010,17(5):395-398.
[4] LORDICK F,OTT K,SENDLER A.Gastric cancer and adenocarcinoma of the esophagogastric junction:principles of neoadjuvant therapy[J].Chirurg,2011,82:968-973.
[5] POPA E C,SHAH M A.Capecitabine in the treatment of esophageal and gastric cancers[J].Expert Opin Investig Drugs,2013,22:1645-1657.
[6] HUANG H,JIANG Z,WANG T,et al.Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer[J].Anticancer Drugs,2012,23:718-723.
[7] SI W,ZHU YY,LI Y,et al.Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer[J].Braz J Med Biol Res,2013,46:1074-1081.
[8] LV H,YAN M,ZHANG M,et al.Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer[J].Chin J Cancer Res,2014,26:692-697.
[9] WADDELL T,GOLLINS S,SOE W,et al.Phase Ⅱ study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer:XelQuali study[J].Cancer Chemother Pharmacol,2011,67:1111-1117.
[10] LI Y H,LUO H Y,WANG F H,et al.Phase Ⅱ study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer[J].J Cancer Res Clin Oncol,2010,136:503-510.
[11] QIU M Z,WEI X L,ZHANG D S,et al.Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients:a prospective observation[J].Tumour Biol,2014,35:4369-4375.
[12] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10.
[13] 孙燕,马胜林.晚期胃癌药物治疗策略和展望[J].中华肿瘤防治杂志,2010,17(5):395-398.
[14] 袁笑,郭涛,陆震,等.324例不同年龄段胃癌患者临床病理资料分析[J].安徽医药,2014,18(9):1679-1681.
[15] YUNG-JUE B,YOUNG-WOO K,HAN-KWANG Y,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315-321. |